Last reviewed · How we verify
Moderate neuromuscular block
At a glance
| Generic name | Moderate neuromuscular block |
|---|---|
| Also known as | Esmeron and Neostigmin/Atropine, Moderate neuromuscular block with rocumeron, moderate relaxation |
| Sponsor | University of Medicine and Pharmacy at Ho Chi Minh City |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Association of Sarcopenia With Rocuronium Use in Liver Transplant Recipients (NA)
- Deep Versus Moderate Neuromuscular Blocking (NA)
- Effect of Neuromuscular Block Depth on Driving Pressure and Postoperative Respiratory Events in Abdominal Surgeries (NA)
- The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer (PHASE2)
- Low Pressure Pneumoperitoneum and Postoperative Ileus (NA)
- Post-Market Study of Low-flow ECCO2R Using PrismaLung+ (NA)
- Individualized Positive End-expiratory Pressure Guided by End-expiratory Lung Volume in the Acute Respiratory Distress Syndrome (PHASE3)
- Bleeding in Laparoscopic Liver Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: